TABLE 2.
Grade three or higher toxicities in patients treated with venetoclax and decitabine or azacitidine.
| Toxicity | ||||
|---|---|---|---|---|
| Toxicity type |
All patients (N = 71)A |
Decitabine‐venetoclax (N = 47)B |
Azacitidine‐venetoclax (N = 24)C |
Significance |
| Hematologic toxicities, grade ≥3 – no. (%) | ||||
| Leukopenia | 64 (90.1) | 43 (91.5) | 21 (87.5) | p = 0.681 |
| Neutropenia | 68 (95.8) | 46 (97.9) | 22 (91.7) | p = 0.262 |
| Lymphocytopenia | 48 (67.6) | 27 (57.4) | 21 (87.5) | p = 0.015 |
| Anemia | 67 (94.4) | 46 (97.9) | 21 (87.5) | p = 0.109 |
| Thrombocytopenia | 65 (91.5) | 46 (97.9) | 19 (79.2) | p = 0.015 |
| Non‐hematologic toxicities, grade ≥3 – no. (%) | ||||
| Neutropenic fever | 31 (43.7) | 22 (46.8) | 9 (37.5) | p = 0.614 |
| Infection | 29 (40.8) | 21 (44.7) | 8 (33.3) | p = 0.447 |
| Respiratory failure | 12 (16.9) | 8 (17.0) | 4 (16.7) | p > 0.999 |
| Arrhythmia | 5 (7.0) | 3 (6.4) | 2 (8.3) | p > 0.999 |
| Hemorrhage | 5 (7.0) | 4 (8.5) | 1 (4.2) | p = 0.656 |
| Hypotension | 4 (5.6) | 3 (6.4) | 1 (4.2) | p > 0.999 |
| AST elevation | 4 (5.6) | 2 (4.3) | 2 (8.3) | p = 0.600 |
| Bilirubin elevation | 4 (5.6) | 1 (2.1) | 3 (12.5) | p = 0.109 |
| Creatinine elevation | 4 (5.6) | 2 (4.3) | 2 (8.3) | p = 0.600 |
| DIC | 3 (4.2) | 2 (4.3) | 1 (4.2) | p > 0.999 |
| Spontaneous TLS | 3 (4.2) | 2 (4.3) | 1 (4.2) | p > 0.999 |
| ALT elevation | 2 (2.8) | 1 (2.1) | 1 (4.2) | p > 0.999 |
| Therapy‐related TLS | 1 (1.4) | 1 (2.1) | 0 (0) | p > 0.999 |
| Death during induction—no. (%)D | ||||
| Death within 30 days | 7 (9.6) | 4 (8.3) | 3 (12.0) | p = 0.685 |
| Death within 60 days | 12 (16.4) | 5 (10.4) | 7 (28.0) | p = 0.093 |
A: Seventy‐one of 74 evaluable patients had at least one toxicity.
B: Forty‐seven of 48 evaluable patients in the decitabine cohort had at least one toxicity.
C: Twenty‐four of 26 evaluable patients in the azacitidine cohort had at least one toxicity.
D: All 48 patients in the decitabine cohort were evaluable for mortality during induction. Death during induction was evaluable in 25 of 26 patients in the azacitidine cohort.